Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02664103
Previous Study | Return to List | Next Study

Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer (METRO-ABC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02664103
Recruitment Status : Completed
First Posted : January 26, 2016
Last Update Posted : February 1, 2018
Sponsor:
Information provided by (Responsible Party):
Sanofi

Brief Summary:

Primary Objectives:

  • To assess the safety for each cohort of patients on a fixed-dose combination pill of capecitabine and cyclophosphamide administered at flat dose and with metronomic schedule (defined as continuous daily treatment without interruption) in patients with metastatic breast cancer.
  • To assess the pharmacokinetics (PKs) and bioavailability of the fixed-dose combination pill of capecitabine and cyclophosphamide administered at different doses/regimens by metronomic schedule in patients with metastatic breast cancer.

Secondary Objectives:

  • To assess antitumor activity of the fixed-dose combination pill of capecitabine and cyclophosphamide administered at different doses/regimens by metronomic schedule in patients with metastatic breast cancer given at 3 different doses and schedules (regimen 1=standard dose twice daily [BID], regimen 2=full dose once daily [OD], regimen 3=low dose [OD])
  • Disease Control Rate (DCR)
  • Overall Response Rate (ORR)
  • Time to Progression (TTP) using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1).
  • To evaluate the compliance under treatment.
  • To describe evolution of toxicities.
  • To assess safety all along patient's treatment.

Condition or disease Intervention/treatment Phase
Breast Cancer Metastatic Drug: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281 Phase 2

Detailed Description:
Primary objective will be evaluated at 12 weeks. Patients who show evidence of efficacy will be treated and followed-up until progression of the disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and Cyclophosphamide Administered at Different Doses/Regimens With Metronomic Schedule in Patients With Metastatic Breast Cancer
Actual Study Start Date : January 23, 2016
Actual Primary Completion Date : November 6, 2017
Actual Study Completion Date : November 6, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: SAR439281(Cohort 1)
Regimen 1: one full-dose tablet containing capecitabine and cyclophosphamide, given BID without interruption
Drug: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281
Pharmaceutical form:Tablet Route of administration: Oral

Experimental: SAR439281(Cohort 2)
Regimen 2: two tablets containing capecitabine and cyclophosphamide, given OD without interruption
Drug: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281
Pharmaceutical form:Tablet Route of administration: Oral

Experimental: SAR439281(Cohort 3)
Regimen 3: one tablet containing capecitabine and cyclophosphamide, given OD without interruption
Drug: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281
Pharmaceutical form:Tablet Route of administration: Oral




Primary Outcome Measures :
  1. Proportion of patients with adverse events [ Time Frame: 12 weeks ]
  2. Assessment of PK parameter: maximum concentration (Cmax) [ Time Frame: Daily 12 weeks ]
  3. Assessment of PK parameter: time to reach Cmax (Tmax) [ Time Frame: Daily 12 weeks ]

Secondary Outcome Measures :
  1. Disease Control Rate (DCR) [ Time Frame: 12 weeks ]
  2. Objective Response Rate (ORR) [ Time Frame: 12 weeks ]
  3. Time to Progression (TTP) [ Time Frame: 12 weeks ]
  4. Proportion of patients compliant with treatment [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Female ≥18 and ≤65 years old.
  • Patients with histologically or cytologically confirmed Metastatic Breast Cancer (HER2 negative, ER/PR positive or negative), who are candidates to receive capecitabine and cyclophosphamide as per Investigator's judgment, and meet either one of the following characteristics:
  • Recurrence of the disease following at least 2 lines of chemotherapy failure for metastatic triple negative breast cancer.
  • In ER/PR positive breast cancer, recurrence of the disease following at least 1 line of chemotherapy failure and 2 lines of hormonal therapy failure.
  • Patients who have been previously treated with capecitabine can be recruited in the study provided:
  • As per the Investigator's opinion, patients will benefit from this chemotherapy AND
  • For prior single administration of capecitabine: at least 6 months has elapsed between last capecitabine treatment and initiation of study treatment.
  • For prior capecitabine-based combination regimen: at least 12 months has elapsed between last capecitabine-based treatment and initiation of study treatment.
  • At least one unidimensionally measurable lesion according to RECIST criteria version 1.1.
  • An Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2.
  • Life expectancy of >3 months.
  • Patients who are willing to undergo (oral) chemotherapy for the treatment of their disease and who are expected to comply with the treatment and study procedures, as per the Investigator's judgment.
  • For women of child bearing potential, documented negative pregnancy test and agreement to use acceptable birth control measures during the duration of the study.
  • Signed Informed consent obtained prior to any study related procedures.

Exclusion criteria:

  • Patients who are HER 2 positive.
  • Patients with 3 or more lines of chemotherapy failure for metastatic triple negative breast cancer.
  • In ER/PR positive breast cancer, recurrence of the disease following 2 or more lines of chemotherapy failure and/or 3 or more lines of hormonal therapy failure.
  • Patients presenting with de novo stage IV metastatic breast cancer, not previously treated for their disease.
  • Patients who have already received any metronomic chemotherapy regimen.
  • Known hypersensitivity to capecitabine or to any of its components.
  • Known hypersensitivity to 5-fluorouracil.
  • Known hypersensitivity to cyclophosphamide or any of its components.
  • History of bladder carcinoma.
  • Systemic anticancer therapy (chemotherapy, hormone therapy, or radiotherapy) within 4 weeks of randomization for the study.
  • History of unexplained hematuria.
  • History of dihydropyrimidine dehydrogenase (DPD) deficiency.
  • Severe renal impairment (creatinine clearance below 30 mL/min [Cockroft and Gault]).
  • Concomitant warfarin treatment.
  • History of significant cardiac disease (eg, unstable angina, congestive heart failure, myocardial infarction, ventricular arrhythmias) within the previous 6 months.
  • Conditions/situations such as:
  • Patient is the Investigator or any Sub-Investigator, research assistant, pharmacist, Study coordinator, other staff, or relative thereof, directly involved in the conduct of the protocol.
  • Uncooperative Patient or any condition that could make the Patient potentially noncompliant to the study procedures.
  • Pregnant or breast-feeding women.
  • Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy.
  • Patients with a possibility of active tuberculosis as suggested by:
  • Any signs or symptoms suggestive of active tuberculosis upon medical history or clinical examination.
  • Chest radiograph within 3 months prior to the screening visit consistent with tuberculosis infection.
  • Patients with close contact with a person with active tuberculosis.
  • Known history of Human Immunodeficiency Virus (HIV).
  • Any other significant medical conditions which in the judgment of the Investigator would preclude completion of the study.
  • Participation in a clinical research study evaluating another investigational drug or therapy within 30 days prior to the Screening Visit.
  • Presence of any of the following laboratory abnormalities at the Screening Visit:
  • Hemoglobin <8.5 g/L;
  • White blood cell (WBC) <3000/μL;
  • Platelet count <100 000/μL;
  • Absolute neutrophil count (ANC) <1500/μL;
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 x upper limit of normal (ULN) (or > 5 x ULN in patients with liver metastasis);
  • Total Bilirubin >1.5 X ULN (or > 2 x ULN in patients with liver metastasis).
  • Patients with a body surface area (BSA) <1.0 m² or 1.8 m².

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02664103


Locations
Layout table for location information
India
Investigational Site Number 356009
Kollkata, India, 700053
Investigational Site Number 356002
Mumbai, India, 400012
Investigational Site Number 356007
New Delhi, India, 110085
Investigational Site Number 356008
Trivandrum, India, 695011
Investigational Site Number 356001
Vellore, India, 632004
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi

Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT02664103     History of Changes
Other Study ID Numbers: CAPCYR07568
U1111-1166-1149 ( Other Identifier: UTN )
First Posted: January 26, 2016    Key Record Dates
Last Update Posted: February 1, 2018
Last Verified: January 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Cyclophosphamide
Capecitabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antimetabolites